Chancellor C. Lowry Barnes, MD, of the University of Arkansas for Medical Sciences (UAMS) and Chancellor Charles Robinson, PhD, of the University of Arkansas, Fayetteville (U of A), announced today the selection of a research team for the inaugural Razorback Research Catalyst, a joint initiative designed to elevate collaborative, high-impact research across both campuses.
The selected proposal, titled “Negative Effects of GLP-1 Receptor Agonists on Bone and Muscle,” is led by Charles O’Brien, PhD, of UAMS and Nicholas Greene, PhD, of the U of A. Their work will explore how medications commonly used to treat diabetes and support weight loss may affect bone strength and muscle health, helping to better understand both the benefits and potential risks of these widely used treatments.
The Razorback Research Catalyst program was developed through a shared vision of U of A Chancellor Robinson and UAMS Chancellor Barnes, whose leadership has emphasized the importance of strategic coordination across the state’s flagship research institutions. Their support has been instrumental in launching a program that brings together complementary strengths in discovery, translational science, and clinical application.
The Catalyst initiative reflects a growing commitment by both institutions to work in a more coordinated and intentional way, strengthening research outcomes through partnership rather than parallel efforts. This approach aligns closely with the U of A’s 150 Forward initiative, which prioritizes research excellence, interdisciplinary collaboration and expanded impact. The Catalyst also aligns with UAMS’ ASPIRE 2033 initiative that demonstrates a commitment to research expansion and increased translation of basic science discoveries into clinical application and community health improvement.